Invion featured in leading industry publication Biotech DailyAustralia's leading independent publication on ASX biotech stocks, Biotech Daily, has featured Invion in its latest article, which was written by acclaimed business journalist and former columnist for The Australian newspaper, Tim Boreham.Tim delved into the interesting background of Invion and the Photosoft technology ahead of its Phase I/II skin cancer trial. He also looked at the many growth options for Invion and concluded that our clinical-stage company was undervalued.Read this article for free at https://www.biotechdaily.com.au/wp/wp-content/uploads/2024/05/IVX-May-3-2024.pdf. The article is NOT commissioned by Invion and views expressed in it are that of the author's.
IVX Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)